Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Sulfasalazine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for The active substance in Sulfasalazine gastro-resistant tablets is sulfasalazine which is an antiinflammatory drug and belongs to a group of medicines called aminosalicylates. Your doctor may give you Sulfasalazine gastro-resistant tablets to treat and manage inflammatory bowel disease or to treat rheumatoid arthritis. Inflammatory bowel disease The main forms of inflammatory bowel disease are Ulcerative Colitis and Crohn's disease. Although the diseases have some features in common, there are some important differences. Ulcerative Colitis is an inflammatory disease which affects only the large bowel (colon and back passage). The lining of the bowel becomes inflamed (red and swollen) and symptoms include abdominal pain and diarrhoea (which may contain blood and mucus). Sulfasalazine gastroresistant tablets are used to control the flare-ups of ulcerative colitis. They may also be used at lower doses to prevent more flare-ups of ulcerative colitis. Crohn's disease is an inflammatory disease which may affect any part of the digestive system from the mouth to the anus, but it most commonly affects the last part of the small bowel and the first part of the large bowel. Symptoms include abdominal pain and diarrhoea (which may be bloody). Sulfasalazine gastro-resistant tablets are used to control the flare-ups of Crohn's Disease. Rheumatoid arthritis Sulfasalazine gastro-resistant tablets are usually given when a group of medicines known as nonsteroidal anti-inflammatory drugs (NSAIDs e.g., aspirin and ibuprofen) are not working. They help prevent damage to your joints and work slowly to reduce swelling and stiffness in your joints.
Page 1 of 9
You must talk to a doctor if you do not feel better or if you feel worse.
e Sulfasalazine gastro-resistant tablets Your doctor will perform complete blood counts and liver function tests before starting Sulfasalazine and every second week during the first three months of therapy. During the second three months, the same tests should be done once monthly and thereafter once every three months, and as clinically indicated. Urine analysis and an assessment of kidney function should also be done in all patients initiating treatment with Sulfasalazine. For patients with baseline renal impairment, treatment with Sulfasalazine should only be initiated if the benefits are considered to outweigh risk. Thereafter, periodic renal function monitoring, especially in the early months of treatment, should be conducted by your doctor during treatment with Sulfasalazine. Treatment should be discontinued if renal function deteriorates. Do not take Sulfasalazine gastro-resistant tablets:
Page 2 of 9
conjunctivitis (red and swollen eyes). These potentially life-threatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin. The highest risk for occurrence of serious skin reactions is within the first weeks of treatment. If you have developed exfoliative dermatitis, Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of Sulfasalazine gastro-resistant tablets you must not be re-started on Sulfasalazine gastro-resistant tablets at any time. If you develop a rash or these skin symptoms, stop taking Sulfasalazine gastro-resistant tablets, seek immediate advice from a doctor and tell your doctor that you are taking this medicine. Severe, life-threatening allergic reactions such as Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported in patients taking various drugs including Sulfasalazine gastro-resistant tablets. It is important to note that early signs of severe allergy, such as fever or swollen lymph nodes, may be present even though rash is not evident. If such signs or symptoms are present, you should seek immediate advice from a doctor. Sulfasalazine gastro-resistant tablets should be discontinued if an alternative cause for the signs or symptoms cannot be established. Children and adolescents Sulfasalazine is not recommended if you are a child and have systemic-onset juvenile rheumatoid arthritis (Stills disease). Tests on your blood, kidneys, liver and urine Your doctor will be taking blood tests to check your blood and your kidneys before you start treatment and regularly during treatment. They will also measure substances produced by your liver known as enzymes (liver function tests) before you start treatment and at regular intervals. They may also test your urine for protein and blood. Other medicines and Sulfasalazine gastro-resistant tablets Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular, the following medicines may interact with Sulfasalazine gastro-resistant tablets:
Page 3 of 9
There have been reports of babies with birth defects of the brain, spine or spinal cord born to mothers who were exposed to sulfasalazine during pregnancy, although the role of sulfasalazine in these defects has not been established. Low sperm count and infertility may occur in men treated with sulfasalazine. Discontinuation of the medicine appears to reverse these effects within 2 to 3 months. Driving and using machines Sulfasalazine gastro-resistant tablets is unlikely to affect your ability to drive or use machinery. Sulfasalazine gastro-resistant tablets contains propylene glycol This medicine contains 5 mg propylene glycol in each tablet.
Sulfasalazine gastro-resistant tablets Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The tablets should be taken with a glass of water and should be swallowed whole. Do not crush, break or chew the tablets. The recommended doses for the following conditions are: For Inflammatory bowel disease: Ulcerative Colitis
2nd Week
Page 4 of 9
3rd Week
4th Week
Morning Evening 1 *etc., to a maximum of 6 tablets per day.
1 1
1 2
2 2*
Do not take more than 6 tablets a day.
Page 5 of 9
Page 6 of 9
• • • • • • •
Fits, jerky, uncontrolled movements Loss of balance Shortness of breath Hair loss Hives Puffiness around the eyes and face Yellowing of the skin or whites of the eyes (jaundice)
Not known (frequency cannot be estimated from the available data)
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Sulfasalazine gastro-resistant tablets
Page 7 of 9
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the bottle after EXP. The expiry date refers to the last day of that month. Store in a dry place. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Sulfasalazine gastro-resistant tablets contain The active substance is sulfasalazine. Each tablet contains 500 mg of sulfasalazine. Other ingredients are maize starch, povidone, magnesium stearate, colloidal silicon dioxide. The tablet enteric coating contains cellulose acetate phthalate, propylene glycol (E1520) (see section 2 Sulfasalazine gastro-resistant tablets contains propylene glycol), macrogol 20,000, bees wax, carnauba wax, self-emulsifying glyceryl monostearate and talc. What Sulfasalazine gastro-resistant tablets looks like and contents of the pack The tablets are yellow in colour, and are oval-shaped. They have "Kph" imprinted on one side and "102", on the other. They are coated with a film, which stops them breaking up until they leave the stomach. The tablets are the colour of the medicine itself. They contain no artificial colouring. Sulfasalazine is supplied in bottles. Each bottle contains 112 tablets. Marketing Authorisation Holder and Manufacturer The marketing authorisation for this medicine is held by: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK. The manufacturer of this medicine is: Recipharm Uppsala AB, Björkgatan 30, Uppsala Domkyrkofors, Uppsala, 753 23, Sweden. For any information about this medicine, please contact Medical Information, Pfizer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS. Telephone 01304 616161. General Advice Because the tablets are coloured yellow they may cause your urine or motions to become a yellow/orange colour. This is normal and harmless but can stain fabric. Any Sulfasalazine soiled fabric should be put in to soak. Difficult stains may be removed with a solution of washing soda. Always test the effect of soda on a small piece of the fabric first. Then apply a mild acid such as white vinegar. Sulfasalazine has caused permanent staining of extended wear soft contact lenses. Although this happened very rarely. Daily-wear soft contact lenses and gas permeable lenses respond to standard cleaning if this happens. This leaflet was last revised in 04/2024
Page 8 of 9
Ref: SZ 26_4
Page 9 of 9
Sulfasalazine 500 mg gastro-resistant tablets comes as tablet containing 500mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Sulfasalazine 500 mg gastro-resistant tablets is sulfasalazine.
Medicines with the same active substance, strength and form include: Salazopyrin En-Tabs 500 mg gastro-resistant tablets, Sulfasalazine 500 mg Tablets. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Sulfasalazine 500 mg gastro-resistant tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
a) Induction and maintenance of remission of ulcerative colitis; treatment of active Crohn's Disease.
b) Treatment of rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (NSAIDs).
This medicine should be used where there is gastro-intestinal intolerance of plain tablets. They should not be crushed or broken. The dose is adjusted according to the severity of the disease and the patient's tolerance to the drug, as detailed below.
Elderly Patients: No special precautions are necessary.
a) Ulcerative colitis
Adults
Severe Attack: 2-4 tablets four times a day may be given in conjunction with steroids as part of an intensive management regime. Rapid passage of the tablets may reduce effect of the drug.
Night-time interval between doses should not exceed 8 hours.
Moderate Attack: 2-4 tablets four times a day may be given in conjunction with steroids.
Mild Attack: 2 tablets four times a day with or without steroids.
Maintenance Therapy: With induction of remission reduce the dose gradually to 4 tablets per day. This dosage should be continued indefinitely, since discontinuance even several years after an acute attack is associated with a four fold increase in risk of relapse.
Paediatric population
The dose is reduced in proportion to body weight.
Acute Attack or relapse:
40- 60 mg/kg per day
Maintenance Dosage:
20 – 30 mg/kg per day
Suspension may provide a more flexible dosage form.
b) Crohn 's Disease
In active Crohn's Disease, this medicine should be administered as in attacks of ulcerative colitis (see above).
c) Rheumatoid Arthritis
Patients with rheumatoid arthritis, and those treated over a long period with NSAIDs, may have sensitive stomachs and for this reason enteric-coated sulfasalazine gastro-resistant tablets are recommended for this disease, as follows:
The patient should start with one tablet daily, increasing his dosage by a tablet a day each week until one tablet four times a day, or two three times a day are reached, according to tolerance and response. Onset of effect is slow and a marked effect may not be seen for six weeks. A reduction in ESR and C-reactive protein should accompany an improvement in joint mobility. NSAIDs may be taken concurrently with sulfasalazine.
Sulfasalazine is contraindicated in:
Infants under the age of 2 years.
Patients with a known hypersensitivity to sulfasalazine, its metabolites or any of the excipients as well as sulfonamides or salicylates.
Patients with porphyria.
Serious infections associated with myelosuppression, including sepsis and pneumonia, have been reported. Patients who develop a new infection while undergoing treatment with sulfasalazine should be monitored closely. Administration of sulfasalazine should be discontinued if a patient develops a serious infection. Caution should be exercised when considering the use of sulfasalazine in patients with a history of recurring or chronic infections or with underlying conditions which may predispose patients to infections.
Complete blood counts, including differential white cell count and liver function tests, should be performed before starting sulfasalazine, and every second week during the first three months of therapy. During the second three months, the same tests should be done once monthly and thereafter once every three months, and as clinically indicated. Baseline assessment of renal function (including urinalysis) is required to be performed in all patients initiating treatment with sulfasalazine. For patients with baseline renal impairment, treatment with sulfasalazine should only be initiated if the benefits are considered to outweigh risk. Thereafter, periodic renal function monitoring, especially in the early months of treatment, should be conducted based on clinical judgment taking baseline renal function into account. Treatment should be discontinued if renal function deteriorates. The patient should also be counselled to report immediately with any sore throat, fever, malaise, pallor, purpura, jaundice or unexpected non-specific illness during sulfasalazine treatment, this may indicate myelosuppression, haemolysis or hepatoxicity. Treatment should be stopped immediately while awaiting the results of blood tests. Please see section 4.4. “Interference with laboratory testing”.
Sulfasalazine should not be given to patients with impaired hepatic function or with blood dyscrasias, unless the potential benefit outweighs the risk.
Sulfasalazine should be given with caution to patients with severe allergy or bronchial asthma.
Severe hypersensitivity reactions may include internal organ involvement, such as hepatitis, nephritis, myocarditis, mononucleosis-like syndrome (i.e., pseudomononucleosis), hematological abnormalities (including hematophagic histiocytosis), and/or pneumonitis including eosinophilic infiltration.
Severe, life-threatening, systemic hypersensitivity reactions such as Drug rash with eosinophilia and systemic symptoms (DRESS) have been reported in patients taking various drugs including sulfasalazine. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately.
Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of sulfasalazine. Patients appear to be at highest risk for these events early in the course of therapy, the onset of the event occurring in the majority of cases within the first month of treatment.
Sulfasalazine should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
Sulfasalazine should be discontinued if an alternative etiology for the signs or symptoms cannot be established.
Use in children with the concomitant condition systemic onset juvenile rheumatoid arthritis may result in a serum sickness like reaction; therefore sulfasalazine is not recommended in these patients.
Since sulfasalazine may cause haemolytic anaemia, it should be used with caution in patients with G-6-PD deficiency.
Oral sulfasalazine inhibits the absorption and metabolism of folic acid and may cause folic acid deficiency (see section 4.6), potentially resulting in serious blood disorders (e.g., macrocytosis and pancytopenia), this can be normalised by administration of folic acid or folinic acid (leucovorin).
Because sulfasalazine causes crystalluria and kidney stone formation, adequate fluid intake should be ensured during treatment.
Oligospermia and infertility may occur in men treated with sulfasalazine. Discontinuation of the drug appears to reverse these effects within 2 to 3 months.
Interference with laboratory testing
Several reports of possible interference with measurements, by liquid chromatography, of urinary normetanephrine causing a false-positive test result have been observed in patients exposed to sulfasalazine or its metabolite, mesalamine/ mesalazine.
Sulfasalazine or its metabolites may interfere with ultraviolet absorbance, particularly at 340 nm, and may cause interference with some laboratory assays that use NAD(H) or NADP(H) to measure ultraviolet absorbance around that wavelength. Examples of such assays may include urea, ammonia, LDH, α-HBDH and glucose. It is possible that alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase-muscle/brain (CK-MB), glutamate dehydrogenase (GLDH), or thyroxine may also show interference when sulfasalazine treatment is given at high doses. Consult with the testing laboratory regarding the methodology used. Caution should be exercised in the interpretation of these laboratory results in patients who are receiving sulfasalazine. Results should be interpreted in conjunction with clinical findings.
Excipient information
This medicine contains propylene glycol (see section 2).
Examples of propylene glycol exposure based on daily dose (see section 4.2) are as follows:
• 16 sulfasalazine 500 mg gastro-resistant tablets administered to an adult weighing 70 kg would result in a propylene glycol exposure of 1.14 mg/kg/day.
• 2 sulfasalazine 500 mg gastro-resistant tablets administered to a 6 year-old child weighing 20 kg would result in a propylene glycol exposure of 0.50 mg/kg/day.
Reduced absorption of digoxin, resulting in non-therapeutic serum levels, has been reported when used concomitantly with oral sulfasalazine.
Sulfonamides bear certain chemical similarities to some oral hypoglycemic agents. Hypoglycemia has occurred in patients receiving sulfonamides. Patients receiving sulfasalazine and hypoglycemic agents should be closely monitored.
Due to inhibition of thiopurine methyltransferase by sulfasalazine, bone marrow suppression and leucopenia have been reported when the thiopurine 6-mercaptopurine or it's prodrug, azathioprine, and oral sulfasalazine were used concomitantly.
Coadministration of oral sulfasalazine and methotrexate to rheumatoid arthritis patients did not alter the pharmacokinetic disposition of the drugs. However, an increased incidence of gastrointestinal adverse events, especially nausea, was reported.
Several reports of possible interference with measurements, by liquid chromatography, of urinary normetanephrine causing a false-positive test result have been observed in patients exposed to sulfasalazine or its metabolite, mesalamine/mesalazine.
Pregnancy
Reproduction studies in rats and rabbits have revealed no evidence of harm to the fetus. Oral sulfasalazine inhibits the absorption and metabolism of folic acid and may cause folic acid deficiency. There have been reports of babies with neural tube defects born to mothers who were exposed to sulfasalazine during pregnancy, although the role of sulfasalazine in these defects has not been established. Because the possibility of harm cannot be completely ruled out, sulfasalazine should be used during pregnancy only if clearly needed.
Breast-feeding
Sulfasalazine and sulfapyridine are found in low levels in breast milk. Patients should avoid breastfeeding while taking this medicine.
There have been reports of bloody stools or diarrhoea in infants who were breastfeeding from mothers on sulfasalazine. In cases where the outcome was reported, bloody stools or diarrhoea resolved in the infant after discontinuation of sulfasalazine in the mother.
Sulfasalazine has no influence on the ability to drive and use machines.
Overall, about 75% of ADRs occur within 3 months of starting therapy, and over 90% by 6 months. Some undesirable effects are dose-dependent and symptoms can often be alleviated by reduction of the dose.
General
Sulfasalazine is split by intestinal bacteria to sulfapyridine and 5-amino salicylate so ADRs to either sulfonamide or salicylate are possible. Patients with slow acetylator status are more likely to experience ADRs related to sulfapyridine. The most commonly encountered ADRs are nausea, headache, rash, loss of appetite and raised temperature.
Specific
The adverse reactions observed during clinical studies conducted with Sulfasalazine have been provided in a single list below by class and frequency (very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1000 to < 1/100); rare (1/10000 to <1/1000); very rare (<1/10000); not known (cannot be estimated from available data)). Where an adverse reaction was seen at different frequencies in clinical studies, it was assigned to the highest frequency reported.
Additional reactions reported from post-marketing experience are included as frequency Not known (cannot be estimated from the available data) in the table below.
MedDRA System Organ Class
Frequency
Adverse Drug Reaction
Infections and Infestations
Not known
aseptic meningitis, pseudomembranous colitis
Blood and lymphatic system disorders
Common
leukopenia
Uncommon
thrombocytopenia**
Not known
agranulocytosis, aplastic anaemia, haemolytic anaemia, heinz body anaemia, hypoprothrombinaemia, lymphadenopathy, macrocytosis, megaloblastic anaemia, methaemoglobinaemina, neutropenia, pancytopenia, pseudomononucleosis**
Immune system disorders
Not known
anaphylaxis*, polyarteritis nodosa, serum sickness
Metabolism and nutrition system disorders
Common
loss of appetite
Not known
folate deficiency**
Psychiatric disorders
Common
insomnia
Uncommon
depression
Not known
hallucinations
Nervous system disorders
Common
dizziness, headache, taste disorders
Uncommon
convulsions
Not known
aseptic meningitis, ataxia, encephalopathy, peripheral neuropathy, smell disorders
Ear and labyrinth disorders
Common
tinnitus
Uncommon
vertigo
Cardiac disorders
Not known
allergic myocarditis**, cyanosis, pericarditis
Vascular disorders
Uncommon
vasculitis
Not known
pallor**
Respiratory, thoracic and mediastinal disorders
Common
cough
Uncommon
dyspnoea
Not known
fibrosing alveolitis, eosinophilic infiltration, interstitial lung disease*, oropharyngeal pain**
Gastrointestinal disorders
Very common
gastric distress, nausea
Common
abdominal pain, diarrhoea*, vomiting*, stomatitis
Not known
aggravation of ulcerative colitis*, pancreatitis, parotitis
Hepatobiliary disorders
Uncommon
jaundice**
Not known
hepatic failure*, hepatitis fulminant*, hepatitis**, hepatitis cholestatic*, cholestasis*
Skin and subcutaneous tissue disorders
Common
pruritus, purpura**
Uncommon
alopecia, urticaria
Not known
drug rash with eosinophilia and systemic symptoms (DRESS)**, epidermal necrolysis (Lyell's syndrome)**, Stevens-Johnson syndrome** , exanthema, exfoliative dermatitis**, angioedema*, toxic pustuloderma, lichen planus, photosensitvity, erythema
Musculoskeletal and connective tissue disorders
Common
arthralgia
Not known
system lupus erythematosus, Sjogren's syndrome
Renal and urinary disorders
Common
proteinuria
Not known
nephrotic syndrome, interstitial nephritis, nephrolithiasis*, haematuria, crystalluria**
Reproductive system and breast disorders
Not known
reversible oligospermia**
General disorders and administration site conditions
Common
fever**
Uncommon
facial edema
Not known
yellow discoloration of skin and body fluids*
Investigations
Uncommon
elevation of liver enzymes
Not known
induction of autoantibodies
Frequency categories: Very common ≥1/10; Common ≥1/100 to <1/10; Uncommon ≥1/1000 to <1/100; Rare ≥1/10000 to <1/1000; Very rare <1/10000; Not known (cannot be estimated from available data)
* ADR identified post-marketing
** see section 4.4 Special warnings and precautions for use
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The drug has low acute per oral toxicity in the absence of hypersensitivity. There is no specific antidote and treatment should be supportive.
Ask anything about Sulfasalazine 500 mg gastro-resistant tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.